ArticleAmerican journal of translational research2026
Efficacy of rhBNP in heart failure with atrial fibrillation combined with poor conventional therapy response and recurrence risk factors.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy of recombinant human brain natriuretic peptide (rhBNP) in patients with acute decompensated heart failure (ADHF) complicated with atrial fibrillation (AF) and poor response to conventional treatment.
methodsThe study included 172 ADHF patients with AF who had poor response to conventional therapy and received rhBNP. Primary observations including changes in blood pressure, C-reactive protein (CRP), heart rate, blood urea nitrogen, oxygen saturation, creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were monitored from admission to discharge. Secondary metrics included left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) taken at the 3-month follow-up. AF recurrence was recorded, and logistic regression analyses were conducted.
resultsAfter treatment with rhBNP, patients' heart rate and blood pressure decreased significantly, oxygen saturation improved, levels of NT-proBNP and CRP decreased, and indicators of renal function improved. At 3 months, LVEF increased and LVESD decreased. Overall, patients in the recurrence group were older, had lower BMI, and showed higher baseline NT-proBNP, CRP, and renal function-related parameters compared with the non-recurrence group. Multivariate analysis demonstrated that low BMI, as well as elevated baseline creatinine, CRP, blood urea nitrogen, and, NT-proBNP were independent risk factors for AF recurrence.
conclusionsrhBNP significantly improves hemodynamics, reduces inflammation, and ameliorates renal function in ADHF patients with AF who respond poorly to conventional therapy. Low BMI and elevated baseline NT-proBNP, CRP, creatinine, and blood urea nitrogen are independent predictors of AF recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.